Show simple item record

dc.contributor.authorStroncek, David F.
dc.contributor.authorJin, Ping
dc.contributor.authorMcKenna, David H.
dc.contributor.authorTakanashi, Minoko
dc.contributor.authorFontaine, Magali J.
dc.contributor.authorPati, Shibani
dc.contributor.authorSchäfer, Richard
dc.contributor.authorPeterson, Emily
dc.contributor.authorBenedetti, Eric
dc.contributor.authorReems, Jo-Anna
dc.date.accessioned2020-07-28T14:24:38Z
dc.date.available2020-07-28T14:24:38Z
dc.date.issued2020-06-16
dc.identifier.urihttp://hdl.handle.net/10713/13424
dc.description.abstractBackground: Culture-derived mesenchymal stromal cells (MSCs) exhibit variable characteristics when manufactured using different methods and different source materials. The purpose of this study was to assess the impact on MSC characteristics when different laboratories propagated MSCs from cultures initiated with BM aliquots derived from the same donor source material. Methods and Methods: Five aliquots from each of three different BM donors were distributed to five independent laboratories. Three laboratories plated whole BM and two laboratories a mononuclear BM cell fraction. Four laboratories cultured in media supplemented with fetal bovine serum (FBS) and one laboratory used human platelet lysate (hPL). Initial cell seeding densities (i.e., P0) ranged from 19.7 × 103/cm2–282 × 103/cm2 and for second seeding (i.e., P1) 0.05 × 103–5.1 × 103 cells/cm2. Post-thawed MSCs from each laboratory were analyzed for cell viability, immunophenotype, tri-lineage differentiation, fibroblast colony-forming units (CFU-F), gene expression, and immunosuppressive activity. Results: Transit times from BM collection to receipt by laboratories located in the United States ranged from 16.0–30.0 h and from 41.5–71.5 h for a laboratory in Asia. Post-thaw culture derived MSCs rom BM #1, #2, and #3 exhibited viabilities that ranged from 74–92%, 61–96%, and 23–90%, respectively. CFU activity from BM #1, #2, and #3 per 200 MSCs plated averaged 45.1 ± 21.4, 49.3 ± 26.8 and 14.9 ± 13.3, respectively. No substantial differences were observed in immunophenotype, and immunosuppressive activities. Global gene expression profiles of MSCs revealed transcriptome differences due to different inter-laboratory methods and to donor source material with the center effects showing greater molecular differences than source material. Conclusion: Functional and molecular differences exist among MSCs produced by different centers even when the same BM starting material is used to initiate cultures. These results indicated that manufacturing of MSCs by five independent centers contributed more to MSC variability than did the source material of the BM used in this study. Thus, emphasizing the importance of establishing worldwide standards to propagate MSCs for clinical use.en_US
dc.description.urihttps://doi.org/10.3389/fcell.2020.00458en_US
dc.language.isoen_USen_US
dc.publisherFrontiers Media SAen_US
dc.relation.ispartofFrontiers in Cell and Developmental Biologyen_US
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.subjectbone marrowen_US
dc.subjectmesenchymal stromal cellsen_US
dc.subjectqualityen_US
dc.subjecttranscriptomeen_US
dc.subjectvariabilityen_US
dc.titleHuman Mesenchymal Stromal Cell (MSC) Characteristics Vary Among Laboratories When Manufactured From the Same Source Material: A Report by the Cellular Therapy Team of the Biomedical Excellence for Safer Transfusion (BEST) Collaborativeen_US
dc.typeArticleen_US
dc.identifier.doi10.3389/fcell.2020.00458
dc.source.volume8


This item appears in the following Collection(s)

Show simple item record

https://creativecommons.org/licenses/by/4.0/
Except where otherwise noted, this item's license is described as https://creativecommons.org/licenses/by/4.0/